Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303232 | 0.88 | ALDH1A1 (0.38) | ALDH1A1GAA | |
| SCHEMBL9904083 | 0.87 | APAF1 (0.34) | ALDH1A1GAA | |
| SCHEMBL25704408 | 0.85 | APAF1 (0.35) | ALDH1A1GAAHRH4 | |
| SCHEMBL4594682 | 0.74 | MAPT (0.41) | ALDH1A1 | |
| SCHEMBL20550342 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL9941093 | 0.71 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| SCHEMBL10515564 | 0.69 | MAPT (0.31) | — | |
| SCHEMBL18766357 | 0.69 | MAPT (0.34) | — | |
| SCHEMBL1189353 | 0.68 | SLC6A2 (0.30) | — | |
| SCHEMBL6129247 | 0.65 | MAPT (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
| EP-3368524-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-2258703-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7205316-B2 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1751130-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| WO-2004067513-A1 | ANTAGONISTS FOR ALPHA-2 ADRENOCEPTORS | OY JUVANTIA PHARMA LTD (FI) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | ALDH1A1 3121/4885GAA 2242/4885HRH4 2/4885 |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | ALDH1A1 1115/4885GAA 3214/4885HRH4 2087/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | ALDH1A1 3121/4885GAA 2242/4885HRH4 2/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | ALDH1A1 1234/4885GAA 3184/4885HRH4 2087/4885 |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | ALDH1A1 1597/4885GAA 2674/4885HRH4 303/4885 |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | ALDH1A1 1597/4885GAA 2674/4885HRH4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.